Clinical Trial Update: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, PK, and PD of Melrilimab (GSK3772847) in healthy participants, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Melrilimab (GSK3772847)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Volunteers, Asthma | Phase 1 | Status: COMPLETED | Results posted: 2021-11-05